Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV -1-Infected Cells

Journal of Virology

Volumn 93, Issue 3, 2019, Pages

  Anand, Sai Priya ^a,b   Prévost, Jérémie ^a,c   Baril, Sophie ^a,c   Richard, Jonathan ^a,c   Medjahed, Halima ^a   Chapleau, Jean Philippe ^a,c   Tolbert, William D ^d   Kirk, Sharon ^e   Smith, Amos B ^e   Wines, Bruce D ^e,f,g,h   Kent, Stephen J ^g   Hogarth, P Mark ^e,f,g   Parsons, Matthew S ^g   Pazgier, Marzena ^d   Finzi, Andrés ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BURNET INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h MONASH UNIVERSITY   (Australia)

Author keywords

Adcc; Anti cluster a antibodies; Anticoreceptor binding site antibodies; Cd4 mimetics; Env; Fcriiia; HIV 1; Nonneutralizing antibodies

Indexed keywords

CD16 ANTIGEN; CORECEPTOR BINDING SITE ANTIBODY; FC RECEPTOR; GLYCOPROTEIN GP 120; PROTEIN FC RECEPTOR IIIA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; EPITOPE; FCGR3A PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; VIROLOGY;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING SITES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; RECEPTORS, IGG; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 85060165375     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01823-18     Document Type: Article

References (76)

1. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT. 2012. ADCC develops over time during persistent infection with liveattenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8:e1002890. https://doi.org/10.1371/jouRNAl.ppat.1002890.
2. Banks ND, Kinsey N, Clements J, Hildreth JE. 2002. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18:1197-1205. https://doi.org/10.1089/08892220260387940.
3. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. 1996. HIV -1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168-2173.
4. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I. 2011. Immune escape from HIV -specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 108:7505-7510. https://doi.org/10.1073/pnas.1016048108.
5. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. 1999. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 180:1338-1341. https://doi.org/10.1086/314988.
6. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. 2012. HIV -specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8:e1002739. https://doi.org/10.1371/jouRNAl.ppat.1002739.
7. Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, Mascola JR, Letvin NL. 2011. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 85:6906-6912. https://doi.org/10.1128/JVI.00326-11.
8. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, KaRNAsuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV -1 vaccine efficacy trial. N Engl J Med 366:1275-1286. https://doi.org/10.1056/NEJMoa1113425.
9. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, Devico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV -1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12.
10. Hogarth PM, Pietersz GA. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11:311-331. https://doi.org/10.1038/nrd2909.
11. Wines BD, Billings H, McLean MR, Kent SJ, Hogarth PM. 2017. Antibody functional assays as measures of Fc receptor-mediated immunity to HIV -new technologies and their impact on the HIV vaccine field. Curr HIV Res 15:202-215. https://doi.org/10.2174/1570162X15666170320112247.
12. Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis GK, Pazgier M. 2014. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV -1 infection. J Virol 88:12895-12906. https://doi.org/10.1128/JVI.02194-14.
13. Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ. 2017. Cooperativity enables nonneutralizing antibodies to neutralize Ebolavirus. Cell Rep 19:413-424. https://doi.org/10.1016/j.celrep.2017.03.049.
14. Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J. 2014. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60:1551-1562. https://doi.org/10.1002/hep.27298.
15. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. https://doi.org/10.1038/nature10373.
16. He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, Miller MS. 2016. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci USA 113:11931-11936. https://doi.org/10.1073/pnas.1609316113.
17. Ding S, Veillette M, Coutu M, Prevost J, Scharf L, Bjorkman PJ, Ferrari G, Robinson JE, Sturzel C, Hahn BH, Sauter D, Kirchhoff F, Lewis GK, Pazgier M, Finzi A. 2016. A highly conserved residue of the HIV -1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anti-cluster A antibodies. J Virol 90:2127-2134. https://doi.org/10.1128/JVI.02779-15.
18. Prevost J, Richard J, Ding S, Pacheco B, Charlebois R, Hahn BH, Kaufmann DE, Finzi A. 2018. Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV -1-infected individuals. Virology 515: 38-45. https://doi.org/10.1016/j.virol.2017.12.002.
19. Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, BeRNArd N, Tremblay C, Kaufmann DE, Roger M, Finzi A. 2015. The HIV -1 gp120 CD4-bound conformation is preferentially targeted by antibodydependent cellular cytotoxicity-mediating antibodies in sera from HIV -1-infected individuals. J Virol 89:545-551. https://doi.org/10.1128/JVI.02868-14.
20. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV -1 envelope epitopes targeted by antibodydependent cell-mediated cytotoxicity. J Virol 88:2633-2644. https://doi.org/10.1128/JVI.03230-13.
21. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schon A, Freire E, Routy J-P, Smith AB, III, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV -1-infected cells to ADCC. Proc Natl Acad Sci USA 112:E2687-E2694. https://doi.org/10.1073/pnas.1506755112.
22. Madani N, Princiotto AM, Mach L, Ding S, Prevost J, Richard J, Hora B, Sutherland L, Zhao CA, Conn BP, Bradley T, Moody MA, Melillo B, Finzi A, Haynes BF, Smith AB, III, Santra S, Sodroski J. 2018. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 9:2363. https://doi.org/10.1038/s41467-018-04758-9.
23. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV -1 Vpu. Nature 451:425-430. https://doi.org/10.1038/nature06553.
24. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV -1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. https://doi.org/10.1016/j.chom.2008.03.001.
25. Veillette M, Richard J, Pazgier M, Lewis GK, Parsons MS, Finzi A. 2016. Role of HIV -1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr HIV Res 14:9-23.
26. Richard J, Prevost J, Alsahafi N, Ding S, Finzi A. 2018. Impact of HIV -1 envelope conformation on ADCC responses. Trends Microbiol 26: 253-265. https://doi.org/10.1016/j.tim.2017.10.007.
27. Forthal DN, Finzi A. 13 November 2018. Antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. AIDS https://doi.org/10.1097/QAD.0000000000002011.
28. Lee WS, Richard J, Lichtfuss M, Smith AB, III, Park J, Courter JR, Melillo BN, Sodroski JG, Kaufmann DE, Finzi A, Parsons MS, Kent SJ. 2016. Antibodydependent cellular cytotoxicity against reactivated HIV -1-infected cells. J Virol 90:2021-2030. https://doi.org/10.1128/JVI.02717-15.
29. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prevost J, Chapleau JP, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B, Martin L, Tremblay C, Hahn BH, Kaufmann DE, Wu X, Smith AB, III, Sodroski J, Pazgier M, Finzi A. 9 September 2016. Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anticluster A ADCC epitopes on HIV -1 envelope glycoproteins. EBioMedicine https://doi.org/10.1016/j.ebiom.2016.09.004.
30. Richard J, Prevost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH, Kaufmann DE, Smith AB, III, Sodroski J, Sauter D, Kirchhoff F, Gee K, Neil SJ, Evans DT, Finzi A. 2017. BST-2 expression modulates small CD4-mimetic sensitization of HIV -1-infected cells to antibody-dependent cellular cytotoxicity. J Virol https://doi.org/10.1128/JVI.00219-17.
31. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK. 2013. Diverse specificity and effector function among human antibodies to HIV -1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA 110:E69-E78. https://doi.org/10.1073/pnas.1217609110.
32. Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M. 2016. Paring down HIV Env: Design and crystal structure of a stabilized inner domain of HIV -1 gp120 displaying a major ADCC target of the A32 region. Structure 24:697-709. https://doi.org/10.1016/j.str.2016.03.005.
33. Tolbert WD, Gohain N, Alsahafi N, Van V, Orlandi C, Ding S, Martin L, Finzi A, Lewis GK, Ray K, Pazgier M. 2017. Targeting the late stage of HIV -1 entry for antibody-dependent cellular cytotoxicity: Structural basis for Env epitopes in the C11 region. Structure 25:1719-1731.e4. https://doi.org/10.1016/j.str.2017.09.009.
34. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD, Sodroski J. 2010. Topological layers in the HIV -1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37:656-667. https://doi.org/10.1016/j.molcel.2010.02.012.
35. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV -1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV -1 serum. J Virol 85: 7029-7036. https://doi.org/10.1128/JVI.00171-11.
36. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69:5723-5733.
37. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. 2016. Dimeric FcgammaR ectodomains as probes of the Fc receptor function of anti-influenza virus IgG. J Immunol 197:1507-1516. https://doi.org/10.4049/jimmunol.1502551.
38. Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Ostergaard L, Sogaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport MP, Emery S, Amin J, Cooper DA, Kan VL, Fox J, Gruell H, Parsons MS, Kent SJ. 1 August 2017. Anti- HIV -1 ADCC antibodies following latency reversal and treatment interruption. J Virol https://doi.org/10.1128/JVI.00603-17.
39. Vanderven HA, Wragg K, Ana-Sosa-Batiz F, Kristensen AB, Jegaskanda S, Wheatley AK, Wentworth D, Wines BD, Hogarth PM, Rockman S, INSIGHT FLU005 Pilot Study Writing Group, Kent SJ. 31 May 2018. Anti-influenza hyperimmune immunoglobulin enhances Fc-functional antibody immunity during human influenza infection. J Infect Dis https://doi.org/10.1093/infdis/jiy328.
40. McLean MR, Madhavi V, Wines BD, Hogarth PM, Chung AW, Kent SJ. 2017. Dimeric Fcgamma receptor enzyme-linked immunosorbent assay to study HIV -specific antibodies: A new look into breadth of Fcgamma receptor antibodies induced by the RV144 Vaccine Trial. J Immunol 199:816-826. https://doi.org/10.4049/jimmunol.1602161.
41. Melillo B, Liang S, Park J, Schon A, Courter JR, LaLonde JM, Wendler DJ, Princiotto AM, Seaman MS, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB, III. 2016. Small-molecule CD4-mimics: Structure-based optimization of HIV -1 entry inhibition. ACS Med Chem Lett 7:330-334. https://doi.org/10.1021/acsmedchemlett.5b00471.
42. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. 2012. Unliganded HIV -1 gp120 core structures assume the CD4-bound conformation with regulation by quateRNAry interactions and variable loops. Proc Natl Acad Sci USA 109:5663-5668. https://doi.org/10.1073/pnas.1112391109.
43. Coutu M, Finzi A. 2015. HIV -1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. J Virol Methods 215-216:37-44. https://doi.org/10.1016/j.jviromet.2015.02.017.
44. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1407-1419. https://doi.org/10.1084/jem.20042510.
45. Richard J, Prevost J, Baxter AE, von Bredow B, Ding S, Medjahed H, Delgado GG, Brassard N, Sturzel CM, Kirchhoff F, Hahn BH, Parsons MS, Kaufmann DE, Evans DT, Finzi A. 2018. Uninfected bystander cells impact the measurement of HIV -specific antibody-dependent cellular cytotoxicity responses. mBio 9:e00358-18. https://doi.org/10.1128/mBio.00358-18.
46. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75:12161-12168. https://doi.org/10.1128/JVI.75.24.12161-12168.2001.
47. Arduin E, Arora S, Bamert PR, Kuiper T, Popp S, Geisse S, Grau R, Calzascia T, Zenke G, Kovarik J. 2015. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. Mol Immunol 63:456-463. https://doi.org/10.1016/j.molimm.2014.09.017.
48. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV . Nature 449:101-104. https://doi.org/10.1038/nature06106.
49. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV -1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682. https://doi.org/10.1038/nature01188.
50. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. https://doi.org/10.1038/31514.
51. Wyatt R, Sodroski J. 1998. The HIV -1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280:1884-1888. https://doi.org/10.1126/science.280.5371.1884.
52. Ma X, Lu M, Gorman J, Terry DS, Hong X, Zhou Z, Zhao H, Altman RB, Arthos J, Blanchard SC, Kwong PD, Munro JB, Mothes W. 2018. HIV -1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. Elife https://doi.org/10.7554/eLife.34271.
53. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB, III, Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV -1 envelope trimers on the surface of native virions. Science 346:759-763. https://doi.org/10.1126/science.1254426.
54. Herschhorn A, Ma X, Gu C, Ventura JD, Castillo-Menendez L, Melillo B, Terry DS, Smith AB, III, Blanchard SC, Munro JB, Mothes W, Finzi A, Sodroski J. 2016. Release of gp120 restraints leads to an entrycompetent intermediate state of the HIV -1 envelope glycoproteins. mBio 7:e01598-16. https://doi.org/10.1128/mBio.01598-16.
55. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV -1: Identification, structures, and B cell ontogenies. Immunity 37:412-425. https://doi.org/10.1016/j.immuni.2012.08.012.
56. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF. 2015. Strainspecific V3 and CD4 binding site autologous HIV -1 neutralizing antibodies select neutralization-resistant viruses. Cell Host Microbe 18:354-362. https://doi.org/10.1016/j.chom.2015.08.006.
57. Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC. 2017. Non-neutralizing antibodies alter the course of HIV -1 infection in vivo. Cell 170:637-648. e610. https://doi.org/10.1016/j.cell.2017.06.048.
58. Alsahafi N, Ding S, Richard J, Markle T, Brassard N, Walker B, Lewis GK, Kaufmann DE, Brockman MA, Finzi A. 2016. Nef proteins from HIV -1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity. J Virol 90:2993-3002. https://doi.org/10.1128/JVI.02973-15.
59. Prevost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T, Tovanabutra S, Hwang KK, Moody MA, Haynes BF, Bonsignori M, Sodroski J, Kaufmann DE, Shaw GM, Chenine AL, Finzi A. 2017. Influence of the envelope gp120 Phe 43 cavity on HIV -1 sensitivity to antibody-dependent cellmediated cytotoxicity responses. J Virol https://doi.org/10.1128/JVI.02452-16.
60. Prevost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, Ochsenbauer C, Finzi A. 13 June 2018. Incomplete downregulation of CD4 expression affects HIV -1 Env conformation and antibody-dependent cellular cytotoxicity responses. J Virol https://doi.org/10.1128/JVI.00484-18.
61. Madhavi V, Kulkarni A, Shete A, Lee WS, McLean MR, Kristensen AB, Ghate M, Wines BD, Hogarth PM, Parsons MS, Kelleher A, Cooper DA, Amin J, Emery S, Thakar M, Kent SJ, ENCORE1 Study Group. 2017. Effect of combination antiretroviral therapy on HIV -1-specific antibodydependent cellular cytotoxicity responses in subtype B- A nd subtype C-infected cohorts. J Acquir Immune Defic Syndr 75:345-353. https://doi.org/10.1097/QAI.0000000000001380.
62. Gohain N, Tolbert WD, Acharya P, Yu L, Liu T, Zhao P, Orlandi C, Visciano ML, Kamin-Lewis R, Sajadi MM, Martin L, Robinson JE, Kwong PD, DeVico AL, Ray K, Lewis GK, Pazgier M. 2015. Cocrystal structures of antibody N60-i3 and antibody JR4 in complex with gp120 define more cluster A epitopes involved in effective antibody-dependent effector function against HIV -1. J Virol 89:8840-8854. https://doi.org/10.1128/JVI.01232-15.
63. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptorbinding site on gp120. Proc Natl Acad Sci USA 101:2706-2711. https://doi.org/10.1073/pnas.0308527100.
64. Zhang Y, Guo J, Huang L, Tian J, Yao X, Liu H. 2018. The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV -1: Insights from molecular dynamics simulation. Chem Biol Drug Des 92:1357-1365. https://doi.org/10.1111/cbdd.13201.
65. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV -1 gp120 core. Science 310:1025-1028. https://doi.org/10.1126/science.1118398.
66. Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, Powell MS, Tan PS, Cendron AC, Wines BD, Scott AM, Hogarth PM. 2011. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 187:3208-3217. https://doi.org/10.4049/jimmunol.1101467.
67. Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, BeRNArd N, Tremblay C, Roger M, Kaufmann DE, Finzi A. 2014. Flow cytometry-based assay to study HIV -1 gp120 specific antibodydependent cellular cytotoxicity responses. J Virol Methods 208:107-114. https://doi.org/10.1016/j.jviromet.2014.08.003.
68. Klein JS, Bjorkman PJ. 2010. Few and far between: How HIV may be evading antibody avidity. PLoS Pathog 6:e1000908. https://doi.org/10.1371/jouRNAl.ppat.1000908.
69. Fontaine J, Chagnon-Choquet J, Valcke HS, Poudrier J, Roger M. 2011. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV -related B-cell disease progression in humans. Blood 117:145-155. https://doi.org/10.1182/blood-2010-08-301887.
70. Fontaine J, Coutlee F, Tremblay C, Routy JP, Poudrier J, Roger M. 2009. HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis 199: 1007-1018. https://doi.org/10.1086/597278.
71. Peretz Y, Ndongala ML, Boulet S, Boulassel MR, Rouleau D, Cote P, Longpre D, Routy JP, Falutz J, Tremblay C, Tsoukas CM, Sekaly RP, BeRNArd NF. 2007. Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: Correlation of these functional T cell subsets with markers of disease progression. Clin Immunol 124:57-68. https://doi.org/10.1016/j.clim.2007.04.004.
72. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, BeRNArd N. 2011. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV -1 coexpressing KIR3DL1∗h/∗y and HLA-B∗57. J Virol 85: 5949-5960. https://doi.org/10.1128/JVI.02652-10.
73. Richard J, Veillette M, Ding S, Zoubchenok D, Alsahafi N, Coutu M, Brassard N, Park J, Courter JR, Melillo B, Smith AB, III, Shaw GM, Hahn BH, Sodroski J, Kaufmann DE, Finzi A. 2016. Small CD4 mimetics prevent HIV -1 uninfected bystander CD4-T cell killing mediated by antibodydependent cell-mediated cytotoxicity. EBioMedicine 3:122-134. https://doi.org/10.1016/j.ebiom.2015.12.004.
74. Harris LJ, Skaletsky E, McPherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275:861-872. https://doi.org/10.1006/jmbi.1997.1508.
75. Sondermann P, Huber R, Oosthuizen V, Jacob U. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267-273. https://doi.org/10.1038/35018508.
76. von Bredow B, Arias JF, Heyer LN, Gardner MR, Farzan M, Rakasz EG, Evans DT. 2015. Envelope glycoprotein inteRNAlization protects human and simian immunodeficiency virus-infected cells from antibodydependent cell-mediated cytotoxicity. J Virol 89:10648-10655. https://doi.org/10.1128/JVI.01911-15.